CD4 T-cell differentiation and inflammatory bowel disease

Trends in Molecular Medicine

Volumn 15, Issue 5, 2009, Pages 199-207

  Zenewicz, Lauren A ^a   Antov, Andrey ^a   Flavell, Richard A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; INTERLEUKIN 10; INTERLEUKIN 22; TRANSFORMING GROWTH FACTOR BETA; USTEKINUMAB;

ANIMAL CELL; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; ENTERITIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFECTION PREVENTION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; BIOLOGICAL THERAPY; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOKINES; DRUG THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 65549098640     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.03.002     Document Type: Review

References (108)

1. Lee G.R., et al. T helper cell differentiation: regulation by cis elements and epigenetics. Immunity 24 (2006) 369-379
2. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6 (2005) 1123-1132
3. Liang S.C., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203 (2006) 2271-2279
4. Nurieva R., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448 (2007) 480-483
5. Ye P., et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194 (2001) 519-527
6. Kolls J.K., and Linden A. Interleukin-17 family members and inflammation. Immunity 21 (2004) 467-476
7. Zheng Y., and Rudensky A.Y. Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8 (2007) 457-462
8. Zhou L., et al. TGF-β-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORγt function. Nature 453 (2008) 236-240
9. Mucida D., et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317 (2007) 256-260
10. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260 (1993) 547-549
11. Kaplan M.H., et al. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382 (1996) 174-177
12. Mullen A.C., et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 292 (2001) 1907-1910
13. Magram J., et al. IL-12-deficient mice are defective in IFN γ production and type 1 cytokine responses. Immunity 4 (1996) 471-481
14. Oxenius A., et al. IL-12 is not required for induction of type 1 cytokine responses in viral infections. J. Immunol. 162 (1999) 965-973
15. Amsen D., et al. The different faces of Notch in T-helper-cell differentiation. Nat. Rev. Immunol. 9 (2009) 116-124
16. Szabo S.J., et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science 295 (2002) 338-342
17. Mullen A.C., et al. Hlx is induced by and genetically interacts with T-bet to promote heritable T(H)1 gene induction. Nat. Immunol. 3 (2002) 652-658
18. Naoe Y., et al. Repression of interleukin-4 in T helper type 1 cells by Runx/Cbf β binding to the Il4 silencer. J. Exp. Med. 204 (2007) 1749-1755
19. Djuretic I.M., et al. Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat. Immunol. 8 (2007) 145-153
20. Ho I.C., et al. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 85 (1996) 973-983
21. Zhu J., et al. Growth factor independent-1 induced by IL-4 regulates Th2 cell proliferation. Immunity 16 (2002) 733-744
22. Shimoda K., et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380 (1996) 630-633
23. Zheng W., and Flavell R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89 (1997) 587-596
24. Fort M.M., et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15 (2001) 985-995
25. - effector T cells. Nat. Immunol. 9 (2008) 1347-1355
26. Veldhoen M., et al. Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 9 (2008) 1341-1346
27. Veldhoen M., et al. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006) 179-189
28. Yang L., et al. IL-21 and TGF-β are required for differentiation of human T(H)17 cells. Nature 454 (2008) 350-352
29. Mangan P.R., et al. Transforming growth factor-β induces development of the T(H)17 lineage. Nature 441 (2006) 231-234
30. Laurence A., et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26 (2007) 371-381
31. + T helper cells. Cell 126 (2006) 1121-1133
32. Yang X.O., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 28 (2008) 29-39
33. Yang X.O., et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282 (2007) 9358-9363
34. Brustle A., et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat. Immunol. 8 (2007) 958-966
35. Quintana F.J., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453 (2008) 65-71
36. Veldhoen M., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453 (2008) 106-109
37. Korn T., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448 (2007) 484-487
38. Wei L., et al. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J. Biol. Chem. 282 (2007) 34605-34610
39. Aggarwal S., et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278 (2003) 1910-1914
40. Langrish C.L., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201 (2005) 233-240
41. Stritesky G.L., et al. IL-23 promotes maintenance but not commitment to the Th17 lineage. J. Immunol. 181 (2008) 5948-5955
42. Annunziato F., et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204 (2007) 1849-1861
43. McGeachy M.J., et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 8 (2007) 1390-1397
44. Zheng Y., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445 (2007) 648-651
45. Fossiez F., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183 (1996) 2593-2603
46. Schwarzenberger P., et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J. Immunol. 161 (1998) 6383-6389
47. Zenewicz L.A., et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 27 (2007) 647-659
48. Zheng Y., et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14 (2008) 282-289
49. Aujla S.J., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat. Med. 14 (2008) 275-281
50. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
51. Wan Y.Y., and Flavell R.A. TGF-β and regulatory T cell in immunity and autoimmunity. J. Clin. Immunol. 28 (2008) 647-659
52. Zheng Y., et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445 (2007) 936-940
53. Wan Y.Y., and Flavell R.A. 'Yin-Yang' functions of transforming growth factor-β and T regulatory cells in immune regulation. Immunol. Rev. 220 (2007) 199-213
54. + regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 204 (2007) 1757-1764
55. Ichiyama K., et al. Foxp3 inhibits RORγt-mediated IL-17A mRNA transcription through direct interaction with RORγt. J. Biol. Chem. 283 (2008) 17003-17008
56. - T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-β. J. Immunol. 178 (2007) 6725-6729
57. + regulatory T cells induced by IL-2 and TGF-β are resistant to Th17 conversion by IL-6. J. Immunol. 180 (2008) 7112-7116
58. + T cells. J. Exp. Med. 205 (2008) 1381-1393
59. Eckburg P.B., et al. Diversity of the human intestinal microbial flora. Science 308 (2005) 1635-1638
60. Hooper L.V., and Gordon J.I. Commensal host-bacterial relationships in the gut. Science 292 (2001) 1115-1118
61. Podolsky D.K. Inflammatory bowel disease. N. Engl. J. Med. 347 (2002) 417-429
62. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3 (2003) 521-533
63. Inoue S., et al. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am. J. Gastroenterol. 94 (1999) 2441-2446
64. Heller F., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129 (2005) 550-564
65. Parronchi P., et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J. Pathol. 150 (1997) 823-832
66. Neurath M.F., et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195 (2002) 1129-1143
67. + T cells. Immunity 1 (1994) 553-562
68. Mizoguchi A., et al. The critical role of interleukin 4 but not interferon γ in the pathogenesis of colitis in T-cell receptor αmutant mice. Gastroenterology 116 (1999) 320-326
69. Wang L.J., et al. Helminth infections and intestinal inflammation. World J. Gastroenterol. 14 (2008) 5125-5132
70. Fujino S., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52 (2003) 65-70
71. Nielsen O.H., et al. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand. J. Gastroenterol. 38 (2003) 180-185
72. Andoh A., et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129 (2005) 969-984
73. Seiderer J., et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm. Bowel Dis 14 (2008) 437-445
74. Duerr R.H., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
75. Dubinsky M.C., et al. IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm. Bowel Dis. 13 (2007) 511-515
76. Yen D., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116 (2006) 1310-1316
77. Uhlig H.H., et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25 (2006) 309-318
78. Hue S., et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203 (2006) 2473-2483
79. Kullberg M.C., et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203 (2006) 2485-2494
80. Izcue A., et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28 (2008) 559-570
81. Becker C., et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J. Immunol. 177 (2006) 2760-2764
82. Hata K., et al. IL-17 stimulates inflammatory responses via NF-κB and MAP kinase pathways in human colonic myofibroblasts. Am. J. Physiol. Gastrointest. Liver Physiol. 282 (2002) G1035-G1044
83. Andoh A., et al. Cooperation of interleukin-17 and interferon-γ on chemokine secretion in human fetal intestinal epithelial cells. Clin. Exp. Immunol. 125 (2001) 56-63
84. Zhang Z., et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm. Bowel Dis. 12 (2006) 382-388
85. Ogawa A., et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin. Immunol. 110 (2004) 55-62
86. Yang X.O., et al. Regulation of inflammatory responses by IL-17F. J. Exp. Med. 205 (2008) 1063-1075
87. Leppkes M., et al. RORγ-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136 (2009) 257-267
88. Niess J.H., et al. Commensal gut flora drives the expansion of proinflammatory CD4 T cells in the colonic lamina propria under normal and inflammatory conditions. J. Immunol. 180 (2008) 559-568
89. Ivanov I.I., et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4 (2008) 337-349
90. Monteleone G., et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-γ production in Crohn's disease. Gastroenterology 128 (2005) 687-694
91. Fantini M.C., et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur. J. Immunol. 37 (2007) 3155-3163
92. Fina D., et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 134 (2008) 1038-1048
93. Zenewicz L.A., et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29 (2008) 947-957
94. Sugimoto K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118 (2008) 534-544
95. Brunkow M.E., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27 (2001) 68-73
96. + T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 179 (1994) 589-600
97. Boden E.K., and Snapper S.B. Regulatory T cells in inflammatory bowel disease. Curr. Opin. Gastroenterol. 24 (2008) 733-741
98. Actis G.C., et al. Mesalamine for inflammatory bowel disease: recent reappraisals. Inflamm. Allergy Drug Targets 7 (2008) 1-5
99. Nielsen O.H., and Munck L.K. Drug insight: aminosalicylates for the treatment of IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4 (2007) 160-170
100. Schwartz M., and Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr. Gastroenterol. Rep. 10 (2008) 585-590
101. Peyrin-Biroulet L., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6 (2008) 644-653
102. Osterman M.T., and Lichtenstein G.R. Current and future anti-TNF therapy for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 10 (2007) 195-207
103. Oppmann B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (2000) 715-725
104. Mannon P.J., et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351 (2004) 2069-2079
105. Wittig B.M. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases. Curr. Opin. Investig. Drugs 8 (2007) 947-954
106. Sandborn W.J., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135 (2008) 1130-1141
107. Ding C., et al. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Curr. Opin. Investig. Drugs 9 (2008) 515-522
108. Fuss I.J., et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12 (2006) 9-15